Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.38 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.38 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP7 | P55210 | 1/20 | 0.33 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27654221 | 1.00 | PTGS2 (0.40) | PTGS2MEN1MAPTKMT2AHPGD | |
| SCHEMBL27691489 | 0.82 | HSD17B10 (0.54) | MEN1MAPTKMT2APOLBHSD17B10 | |
| SCHEMBL27691488 | 0.82 | HSD17B10 (0.54) | MEN1MAPTKMT2APOLBHSD17B10 | |
| SCHEMBL473167 | 0.80 | ELANE (0.37) | PTGS2ELANEHSD17B10L3MBTL1 | |
| SCHEMBL473165 | 0.80 | ELANE (0.37) | PTGS2ELANEHSD17B10L3MBTL1 | |
| SCHEMBL949093 | 0.79 | PTGS2 (0.46) | PTGS2MEN1MAPTKMT2AELANE | |
| SCHEMBL15799335 | 0.78 | ELANE (0.35) | PTGS2MEN1MAPTKMT2AELANE | |
| SCHEMBL7699724 | 0.77 | ELANE (0.41) | PTGS2MEN1MAPTKMT2AELANE | |
| SCHEMBL473144 | 0.77 | CASP1 (0.48) | ELANECASP1CASP3CASP7CASP8 | |
| SCHEMBL473145 | 0.77 | CASP1 (0.48) | ELANECASP1CASP3CASP7CASP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-20 | — | — | US | disclosed |
| US-7772366-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-10 | — | — | US | disclosed |
| CN-101775012-A | Aspartic acid specific cysteine proteinase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPO | 2010-07-14 | — | — | CN | disclosed |
| CN-1812972-B | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPO | 2010-04-28 | — | — | CN | disclosed |
| EP-2123665-A2 | Inhibitors of interleukin-1Beta converting enzyme | Vertex Pharmaceuticals Incorporated (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-20 | — | — | US | disclosed |
| US-7288624-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
| CN-1812972-A | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPO (US) | 2006-08-02 | — | — | CN | disclosed |
| EP-1394175-A1 | Inhibitors of interleukin-1beta converting enzyme | Vertex Pharmaceuticals Incorporated (US) | 2004-03-03 | — | — | EP | disclosed |
| EP-0804464-B1 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | CORVAS INT INC (US) | 2002-05-08 | — | — | EP | disclosed |
| US-6342504-B1 | PEPTIDES AS ANTITHROMBINS AND ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. | 2002-01-29 | — | — | US | disclosed |
| US-6103711-A | INTERLEUKIN-1 MEDIATED DISEASES; ANTIINFLAMMATORY AND -CARCINOGENIC AGENTS; AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2000-08-15 | — | — | US | disclosed |
| US-6011158-A | PEPTIDE ALDEHYDE COMPOUNDS HAVING ARGININE OR ARGININE MIMICS AT P1 AND PYRIDONE, PYRIMIDONE, OR URACIL GROUPS AS PART OF THE PEPTIDE BACKBONE. THESE COMPOUNDS ARE POTENT INHIBITORS OF THROMBIN IN VIVO AND IN VITRO. | CORVAS INTERNATIONAL, INC. (US) | 2000-01-04 | — | — | US | disclosed |
| US-6008351-A | PEPTIDE ALDEHYDE COMPOUNDS HAVING URACIL OR PYRIMIDIN-4-ONE GROUPS AS PART OF THE PEPTIDE BACKBONE; POTENT INHIBITORS OF THROMBIN | CORVAS INTERNATIONAL, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| US-5973111-A | NOVEL COMPOUNDS THAT ARE CAPABLE OF BINDING TO THE ACTIVE SITE OF INTERLEUKIN-1B-CONVERTING ENZYME (ICE) AND INHIBITING ACTIVITY OF THAT ENZYME; ADMINISTERING TO TREAT INFLAMMATORY, AUTOIMMUNE, AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1999-10-26 | — | — | US | disclosed |
| US-5658930-A | THROMBIN INHIBITORS | CORVAS INTERNATIONAL, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5656627-A | USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES | VERTEX PHARMACEUTICALS, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5656645-A | INHIBITORS OF THROMBIN | CORVAS INTERNATIONAL, INC. (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1996018644-A9 | AROMATIC HETEROCYCLIC DERIVATIVES AS ENZYME INHIBITORS | — | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070953-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | PTGS2 443/4885MEN1 1388/4885MAPT 115/4885 |
| US-20110015371-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1R1 | PTGS2 443/4885MEN1 1388/4885MAPT 115/4885 |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | PTGS2 443/4885MEN1 1388/4885MAPT 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.